SEC Filings
Dyne Therapeutics' Mid-Stage DM1 Trial Shows Broad One-Year Gains Across Strength, Function, And Patient-Reported Outcomes
Z-basivarsen cut hand-opening time by 3.2 seconds at six months and diverged from a natural history control group at 12 months across four measures.